Effect of pirfenidone on the short- and long-term outcomes in pulmonary infection-related acute respiratory distress syndrome: a prospective cohort study.
文献摘要
Background Pirfenidone, approved for idiopathic pulmonary fibrosis (IPF), slows lung function decline and reduces fibrosis, including in post-COVID-19 pulmonary fibrosis. Its early use in acute respiratory distress syndrome (ARDS) remains uncertain. This study evaluated the effects of early pirfenidone administration on short- and long-term outcomes in pulmonary infection-related ARDS. Methods In this prospective cohort study, 97 ARDS patients were consecutively recruited and assigned to Pirfenidone (n = 29), Glucocorticoid (n = 38), or Control (n = 30) groups according to the severity and clinical course of the disease by the attending clinical team, all receiving standard care. Short-term outcomes included 28-day mortality, ICU length of stay, and hospital length of stay. Long-term outcomes at 3 and 6 months included chest CT fibrosis score, pulmonary function [forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO)], SpO 2 /FiO 2 ratio, modified Medical Research Council (mMRC) dyspnea score, and Activities of Daily Living (ADL) score. Safety was assessed via adverse events and laboratory parameters. Results At 6 months, the Pirfenidone Group had significantly lower chest CT fibrosis scores than the Glucocorticoid Group [3.0 (0.0-6.5) vs. 6.0 (4.0-8.0), p 2 /FiO 2 , and ADL scores at 3 and 6 months were significantly higher in the Pirfenidone Group compared with both Glucocorticoid and Control groups (all p 0.05). No severe drug-related adverse events were observed. Conclusion Early pirfenidone administration in pulmonary infection-related ARDS enhances long-term functional recovery and reduces fibrosis without increasing safety risks, although it does not significantly impact short-term outcomes. These findings support the consideration of early antifibrotic therapy in ARDS management.